Clinical Behavior of the Asqelio™ Trifocal Diffractive Intraocular Lens

Retrospective Study on the Clinical Behavior of the Asqelio™ Trifocal Diffractive Intraocular Lens With Follow-up at 3 Months

The main objective of this study was to evaluate distance, intermediate, and near vision in patients who have undergone cataract extraction with bilateral implantation of a new hydrophobic trifocal diffractive intraocular lens (IOL) with a biospheric design, the Asqelio Trifocal IOL (AST Products, Inc., Billerica MA, USA), along with patient-reported outcomes (PRO). For that purpose the clinical information of 50 eyes from 25 patients was retrospectively analyzed 3 months after implantation

Inclusion Criteria:

• 50 years or older submitted to cataract surgery with binocular implantation of Asqelio Trifocal TFLIO130C IOL
• Seeking spectacle independence after surgery
• IOL power between +5.0D y +34.0D
• Transparent ocular media, except for the cataract prior to surgery.
• Potential postoperatory visual acuity of 20/25 or better, as assessed prior to surgery

Exclusion Criteria:

• Preoperatory corneal astigmatism greater than 1.0D
• Previous corneal surgery or trauma
• Irregular cornea (e.g. keratoconus)
• Choroidal hemorrhage
• Microftalmos
• Severe corneal dystrophy
• Uncontrolled or medically controlled glaucoma
• Clinically significant macular changes
• Severe concomitant ocular condition
• Cataract not age-related
• Severe optic nerve atrophy
• Diabetic retinopathy
• Ambyopia
• Extremely shallow anterior chamber
• Severe chronic uveitis
• Pregnancy or lactating
• Rubella
• Mature/dense cataract difficulting preoperatory eye fundus assessment
• Previous retinal detachment
• Concurrent participation in another investigation involving drugs or medical devices